Australia’s drug regulatory agency, the Therapeutic Goods Administration (TGA) announced on 17 April 2018 that it had established a new chemical entity work-sharing pilot with Health Canada.
New chemical entities added to ACSS work-sharing pilot
Home/Policies & Legislation | Posted 25/05/2018 0 Post your comment
Australian and Canadian officials are entering into the pilot project as part of the Australia-Canada-Singapore-Switzerland (ACSS) Consortium. The ACSS Consortium is a collaborative initiative of like-minded, medium-sized regulatory authorities and includes the TGA, Health Canada, Singapore’s Health Sciences Authority (HSA) and the Swiss Agency for Therapeutic Products (Swissmedic).
The New Chemical Entities (NCE) Working Group was formed to focus on developing opportunities within regulatory programme through the greater alignment of regulatory approaches and technical requirements.
Under the programme, the two regulatory bodies will collaborate on reviewing NCE files to increase efficiency. Each agency will evaluate its respective Module 1 and process Module 5, which covers clinical matters, separately. Health Canada will then evaluate the quality-focused Module 3, while the TGA will take the lead on the toxicology-focussed Module 4. They will then assess the practicalities of undertaking a coordinated assessment that will complement the regulatory decision-making within each jurisdiction.
The NCE pilot follows an expansion of the ACSS generic drug work-sharing trial in December 2017.
Related article
Comments on TGA’s modified approach to naming biologicals
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.
Source: TGA
Guidelines
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
EMA concept paper towards a tailored clinical approach in biosimilar development
Public consultation for the modification of the biosimilars regulation in Brazil
Comments (0)
Post your comment